Skip to main content
Erschienen in: Clinical Research in Cardiology 4/2011

01.04.2011 | Original Paper

Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry)

verfasst von: Anselm K. Gitt, Claus Jünger, Christina Jannowitz, Barbara Karmann, Jochen Senges, Kurt Bestehorn

Erschienen in: Clinical Research in Cardiology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Objectives

According to various national and international guidelines, the target LDL-C level is <100 mg/dl for patients with established coronary heart disease (CHD) or CHD risk equivalent (CE). We aimed to investigate aspects of the lipid-lowering management of patients at high cardiovascular risk in-hospital care and the achievement of target values.

Methods

In the internet-based 2L registry in Germany (2005–2006), cardiologists in 42 hospitals documented at a single visit 3,131 consecutive patients with known CHD, and/or diabetes mellitus, peripheral arterial disease, or a 10-year CHD risk >20% (summarized as CE), who were on chronic statin treatment. They received instructions on the guidelines and instant feedback on the effect of their treatment decisions (educational study component).

Results

The three groups comprised 1,458 patients with CHD + CE (46.6%; median LDL-C 107 mg/dl), 1,104 patients with CHD only (35.3%; median LDL-C 104 mg/dl), and 569 with CE only (18.2%; median LDL-C 111 mg/dl). At admission, LDL-C levels <100 mg/dl were observed in 43.1, 44.8 and 37.9% of patients in the three groups, respectively. Statin doses at admission were usually in the low to intermediate range (e.g., simvastatin 10–20 mg/day). Cardiologists switched to another statin in 14.6%, increased the dose of statins (if same drug) in 22.9% (mean increase from 26.8 mg/day at baseline to 31.6 mg/day) and/or added a cholesterol absorption inhibitor (CAI) in 11.6%. The cardiologists’ intervention improved estimated LDL-C levels (using a lipid calculator); however, the 100 mg/dl LDL-C target was only reached in 49.0, 48.5, and 42.9%.

Conclusions

When compared with earlier studies in the outpatient setting, the treatment to target for LDL-C of high-risk CHD patients has improved, but is not satisfactory.
Literatur
1.
Zurück zum Zitat Assmann G, Schulte H, Cullen P, Neiss A, Bestehorn K (2007) Treatment of hyperlipidemia in primary practise in Germany: sub-group analyses from the 4E-registry with particular emphasis on men and women with diabetes mellitus. Exp Clin Endocrinol Diabetes 115:85–91PubMedCrossRef Assmann G, Schulte H, Cullen P, Neiss A, Bestehorn K (2007) Treatment of hyperlipidemia in primary practise in Germany: sub-group analyses from the 4E-registry with particular emphasis on men and women with diabetes mellitus. Exp Clin Endocrinol Diabetes 115:85–91PubMedCrossRef
2.
Zurück zum Zitat Assmann G, Schulte H, Cullen P, Seedorf U (2007) Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Invest 37:925–932PubMedCrossRef Assmann G, Schulte H, Cullen P, Seedorf U (2007) Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Invest 37:925–932PubMedCrossRef
3.
Zurück zum Zitat Bakris G, Bohm M, Dagenais G, Diener HC, Fujita T, Gorelick P, Kjeldsen SE, Laakso M, Mancia G, Pitt B, Sharma A, Sleight P, Teo K, Unger T, Weber M, Williams B, Zannad F (2008) Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol 97:713–725PubMedCrossRef Bakris G, Bohm M, Dagenais G, Diener HC, Fujita T, Gorelick P, Kjeldsen SE, Laakso M, Mancia G, Pitt B, Sharma A, Sleight P, Teo K, Unger T, Weber M, Williams B, Zannad F (2008) Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol 97:713–725PubMedCrossRef
4.
Zurück zum Zitat Bestehorn K, Jannowitz C, Karmann B, Pittrow D, Kirch W (2009) Characteristics, management and attainment of lipid target levels in patients enrolled in Disease Management Program versus those in routine care: LUTZ registry. BMC Public Health 9:280PubMedCrossRef Bestehorn K, Jannowitz C, Karmann B, Pittrow D, Kirch W (2009) Characteristics, management and attainment of lipid target levels in patients enrolled in Disease Management Program versus those in routine care: LUTZ registry. BMC Public Health 9:280PubMedCrossRef
5.
Zurück zum Zitat Bestehorn K, Schäfer J, Gitt A, Jannowitz C, Karmann B, Sonntag FJ, Weizel A (2008) Leitliniengerechte Lipidtherapie und Zielwerterreichung bei Risikopatienten im klinischen Alltag. Rationale, Ziele und Design des LIMA-Registers. MMW Fortschr Med 150 Suppl:135–141 Bestehorn K, Schäfer J, Gitt A, Jannowitz C, Karmann B, Sonntag FJ, Weizel A (2008) Leitliniengerechte Lipidtherapie und Zielwerterreichung bei Risikopatienten im klinischen Alltag. Rationale, Ziele und Design des LIMA-Registers. MMW Fortschr Med 150 Suppl:135–141
6.
Zurück zum Zitat Bischoff B, Silber S, Richartz BM, Pieper L, Klotsche J, Wittchen HU (2006) Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany. Clin Res Cardiol 95:405–412PubMedCrossRef Bischoff B, Silber S, Richartz BM, Pieper L, Klotsche J, Wittchen HU (2006) Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany. Clin Res Cardiol 95:405–412PubMedCrossRef
7.
Zurück zum Zitat Bohler S, Scharnagel H, Freisinger F, Stojakovic T, Glaesmer H, Klotsche J, Pieper L, Pittrow D, Kirch W, Schneider H, Stalla GK, Lehnert H, Zeiher AM, Silber S, Koch U, Ruf G, Marz W, Wittchen HU (2006) Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis. doi:10.1016/j.atherosclerosis.2006.02.025 Bohler S, Scharnagel H, Freisinger F, Stojakovic T, Glaesmer H, Klotsche J, Pieper L, Pittrow D, Kirch W, Schneider H, Stalla GK, Lehnert H, Zeiher AM, Silber S, Koch U, Ruf G, Marz W, Wittchen HU (2006) Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis. doi:10.​1016/​j.​atherosclerosis.​2006.​02.​025
8.
Zurück zum Zitat Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, the Pravastatin or Atorvastatin Evaluation, Infection Therapy—Thrombolysis in Myocardial Infarction 22 Investigators (2004) Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMedCrossRef Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, the Pravastatin or Atorvastatin Evaluation, Infection Therapy—Thrombolysis in Myocardial Infarction 22 Investigators (2004) Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504PubMedCrossRef
9.
Zurück zum Zitat Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264–1272PubMedCrossRef Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264–1272PubMedCrossRef
10.
Zurück zum Zitat D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P (2001) Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286:180–187PubMedCrossRef D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P (2001) Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286:180–187PubMedCrossRef
11.
Zurück zum Zitat Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM (2005) Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96:556–563PubMedCrossRef Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM (2005) Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96:556–563PubMedCrossRef
12.
Zurück zum Zitat Diehm C, Schuster A, Allenberg H, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G, Trampisch H (2004) High prevalence of peripheral arterial disease and comorbidity in 6,880 primary care patients: cross sectional study. Atherosclerosis 172:95–105PubMedCrossRef Diehm C, Schuster A, Allenberg H, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G, Trampisch H (2004) High prevalence of peripheral arterial disease and comorbidity in 6,880 primary care patients: cross sectional study. Atherosclerosis 172:95–105PubMedCrossRef
13.
Zurück zum Zitat Fagan T (1994) Remembering the lessons of basic pharmacology. Arch Intern Med 154:1430–1431PubMedCrossRef Fagan T (1994) Remembering the lessons of basic pharmacology. Arch Intern Med 154:1430–1431PubMedCrossRef
15.
Zurück zum Zitat Friedmann PD, Brett AS, Mayo-Smith MF (1996) Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 124:414–421PubMed Friedmann PD, Brett AS, Mayo-Smith MF (1996) Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 124:414–421PubMed
16.
Zurück zum Zitat Gitt AK, Juenger C, Jannowitz C, Karmann B, Senges J, Bestehorn K (2009) Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil 16:438–444PubMedCrossRef Gitt AK, Juenger C, Jannowitz C, Karmann B, Senges J, Bestehorn K (2009) Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil 16:438–444PubMedCrossRef
17.
Zurück zum Zitat Gohlke H, Kubler W, Mathes P, Meinertz T, Schuler G, Gysan DB, Sauer G (2001) Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group. Z Kardiol 90:148–149PubMedCrossRef Gohlke H, Kubler W, Mathes P, Meinertz T, Schuler G, Gysan DB, Sauer G (2001) Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group. Z Kardiol 90:148–149PubMedCrossRef
18.
Zurück zum Zitat Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227–239PubMedCrossRef Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227–239PubMedCrossRef
19.
Zurück zum Zitat Hildemann SK, Barho C, Karmann B, Darius H, Bestehorn K (2007) Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin 23:713–719PubMedCrossRef Hildemann SK, Barho C, Karmann B, Darius H, Bestehorn K (2007) Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin 23:713–719PubMedCrossRef
20.
Zurück zum Zitat Hildemann SK, Barho C, Karmann B, Darius H, Bode C (2008) Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Curr Med Res Opin 24:2777–2784 Hildemann SK, Barho C, Karmann B, Darius H, Bode C (2008) Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Curr Med Res Opin 24:2777–2784
21.
Zurück zum Zitat Kanstrup H, Lassen JF, Heickendorff L, Lauritzen T, Larsen ML (2004) Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients. J Intern Med 255:367–372PubMedCrossRef Kanstrup H, Lassen JF, Heickendorff L, Lauritzen T, Larsen ML (2004) Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients. J Intern Med 255:367–372PubMedCrossRef
22.
Zurück zum Zitat Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH (2007) Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation 115:1363–1370PubMedCrossRef Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH (2007) Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation 115:1363–1370PubMedCrossRef
24.
Zurück zum Zitat Lange S, Trampisch HJ, Haberl R, Darius H, Pittrow D, Schuster A, von Stritzky B, Tepohl G, Allenberg JR, Diehm C (2005) Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level. Atherosclerosis 178:351–357PubMedCrossRef Lange S, Trampisch HJ, Haberl R, Darius H, Pittrow D, Schuster A, von Stritzky B, Tepohl G, Allenberg JR, Diehm C (2005) Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level. Atherosclerosis 178:351–357PubMedCrossRef
25.
Zurück zum Zitat Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 326:1423–1430CrossRef Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 326:1423–1430CrossRef
26.
Zurück zum Zitat Marma AK, Lloyd-Jones DM (2009) Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation 120:384–390PubMedCrossRef Marma AK, Lloyd-Jones DM (2009) Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation 120:384–390PubMedCrossRef
28.
Zurück zum Zitat Mosca L (2007) Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol 10:19–25PubMedCrossRef Mosca L (2007) Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol 10:19–25PubMedCrossRef
29.
Zurück zum Zitat Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL (2005) National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 111:499–510PubMedCrossRef Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL (2005) National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 111:499–510PubMedCrossRef
31.
Zurück zum Zitat Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgstrom F, Jonsson L (2006) Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs 6:121–128PubMedCrossRef Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgstrom F, Jonsson L (2006) Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs 6:121–128PubMedCrossRef
32.
Zurück zum Zitat Ovbiagele B, Liebeskind DS, Kim D, Ali LK, Pineda S, Saver JL (2010) Prognostic value of Framingham Cardiovascular Risk Score in hospitalized stroke patients. J Stroke Cerebrovasc Dis Ovbiagele B, Liebeskind DS, Kim D, Ali LK, Pineda S, Saver JL (2010) Prognostic value of Framingham Cardiovascular Risk Score in hospitalized stroke patients. J Stroke Cerebrovasc Dis
33.
Zurück zum Zitat Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J (2005) A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 80:587–595PubMedCrossRef Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J (2005) A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 80:587–595PubMedCrossRef
34.
Zurück zum Zitat Persell SD, Lloyd-Jones DM, Baker DW (2006) Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med 21:171–176PubMed Persell SD, Lloyd-Jones DM, Baker DW (2006) Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med 21:171–176PubMed
35.
Zurück zum Zitat Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD (1999) Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47:749–754PubMed Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD (1999) Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47:749–754PubMed
36.
Zurück zum Zitat Ruof J, Klein G, Marz W, Wollschlager H, Neiss A, Wehling M (2002) Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 35:48–53PubMedCrossRef Ruof J, Klein G, Marz W, Wollschlager H, Neiss A, Wehling M (2002) Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 35:48–53PubMedCrossRef
37.
Zurück zum Zitat Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88–136PubMedCrossRef Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88–136PubMedCrossRef
38.
Zurück zum Zitat Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D (2009) Systematic review: comparative effectiveness and harms of combinations of lipid-modifying agents and high-dose statin monotherapy. Ann Intern Med, p 151 [Epub ahead of print] Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D (2009) Systematic review: comparative effectiveness and harms of combinations of lipid-modifying agents and high-dose statin monotherapy. Ann Intern Med, p 151 [Epub ahead of print]
39.
Zurück zum Zitat Silber S, Jarre F, Pittrow D, Klotsche J, Pieper L, Zeiher A, Wittchen H, for the DETECT Study Group Cardiovascular risk assessment in primary care (DETECT) (2008) What is the concordance between physician assessment and established risk scores? Med Klin 103(9):638–645 (article in German)CrossRef Silber S, Jarre F, Pittrow D, Klotsche J, Pieper L, Zeiher A, Wittchen H, for the DETECT Study Group Cardiovascular risk assessment in primary care (DETECT) (2008) What is the concordance between physician assessment and established risk scores? Med Klin 103(9):638–645 (article in German)CrossRef
40.
Zurück zum Zitat Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363–2372PubMedCrossRef Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113:2363–2372PubMedCrossRef
41.
Zurück zum Zitat Steg PG, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197–1206PubMedCrossRef Steg PG, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197–1206PubMedCrossRef
42.
Zurück zum Zitat Valuck RJ, Williams SA, MacArthur M, Saseen JJ, Nair KV, McCollum M, Ensor JE (2003) A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 25:2936–2957PubMedCrossRef Valuck RJ, Williams SA, MacArthur M, Saseen JJ, Nair KV, McCollum M, Ensor JE (2003) A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 25:2936–2957PubMedCrossRef
43.
Zurück zum Zitat Völler H, Reibis R, Pittrow D, Jannowitz C, Wegscheider K, Karmann B, Bestehorn K (2009) Secondary prevention of diabetic patients with coronary artery disease in cardiac rehabilitation: risk factors, treatment and target level attainment. Curr Med Res Opin 25:879–890PubMedCrossRef Völler H, Reibis R, Pittrow D, Jannowitz C, Wegscheider K, Karmann B, Bestehorn K (2009) Secondary prevention of diabetic patients with coronary artery disease in cardiac rehabilitation: risk factors, treatment and target level attainment. Curr Med Res Opin 25:879–890PubMedCrossRef
Metadaten
Titel
Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry)
verfasst von
Anselm K. Gitt
Claus Jünger
Christina Jannowitz
Barbara Karmann
Jochen Senges
Kurt Bestehorn
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Clinical Research in Cardiology / Ausgabe 4/2011
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-010-0240-9

Weitere Artikel der Ausgabe 4/2011

Clinical Research in Cardiology 4/2011 Zur Ausgabe

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.